Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oxeia Biopharmaceuticals, Inc.

http://www.oxeiabiopharma.com/index.php

Latest From Oxeia Biopharmaceuticals, Inc.

Vasopharm Sees Path Forward For Traumatic Brain Injury Drug

Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
UsernamePublicRestriction

Register